228 related articles for article (PubMed ID: 26784938)
21. Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.
Yoon H; Cho HY; Yoo HD; Kim SM; Lee YB
AAPS J; 2013 Apr; 15(2):571-80. PubMed ID: 23417334
[TBL] [Abstract][Full Text] [Related]
22. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
Müller F; Pontones CA; Renner B; Mieth M; Hoier E; Auge D; Maas R; Zolk O; Fromm MF
Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
[TBL] [Abstract][Full Text] [Related]
23. Contribution of MATE1 to Renal Secretion of the NMDA Receptor Antagonist Memantine.
Müller F; Weitz D; Derdau V; Sandvoss M; Mertsch K; König J; Fromm MF
Mol Pharm; 2017 Sep; 14(9):2991-2998. PubMed ID: 28708400
[TBL] [Abstract][Full Text] [Related]
24. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).
Li Q; Guo D; Dong Z; Zhang W; Zhang L; Huang SM; Polli JE; Shu Y
Toxicol Appl Pharmacol; 2013 Nov; 273(1):100-9. PubMed ID: 24001450
[TBL] [Abstract][Full Text] [Related]
25. The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.
Hibma JE; Zur AA; Castro RA; Wittwer MB; Keizer RJ; Yee SW; Goswami S; Stocker SL; Zhang X; Huang Y; Brett CM; Savic RM; Giacomini KM
Clin Pharmacokinet; 2016 Jun; 55(6):711-21. PubMed ID: 26597253
[TBL] [Abstract][Full Text] [Related]
26. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations.
König J; Zolk O; Singer K; Hoffmann C; Fromm MF
Br J Pharmacol; 2011 Jun; 163(3):546-55. PubMed ID: 20883471
[TBL] [Abstract][Full Text] [Related]
27. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
Ito S; Kusuhara H; Yokochi M; Toyoshima J; Inoue K; Yuasa H; Sugiyama Y
J Pharmacol Exp Ther; 2012 Feb; 340(2):393-403. PubMed ID: 22072731
[TBL] [Abstract][Full Text] [Related]
28. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacogenet Genomics; 2010 Jan; 20(1):38-44. PubMed ID: 19898263
[TBL] [Abstract][Full Text] [Related]
29. Genetic variants of the organic cation transporter 2 influence the disposition of metformin.
Song IS; Shin HJ; Shim EJ; Jung IS; Kim WY; Shon JH; Shin JG
Clin Pharmacol Ther; 2008 Nov; 84(5):559-62. PubMed ID: 18401339
[TBL] [Abstract][Full Text] [Related]
30. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
[TBL] [Abstract][Full Text] [Related]
31. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
[TBL] [Abstract][Full Text] [Related]
32. Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression.
Kalamajski S; Huang M; Dalla-Riva J; Keller M; Dawed AY; Hansson O; Pearson ER; ; Mulder H; Franks PW
Hum Mol Genet; 2022 Feb; 31(4):491-498. PubMed ID: 34505146
[TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacokinetics of metformin.
Graham GG; Punt J; Arora M; Day RO; Doogue MP; Duong JK; Furlong TJ; Greenfield JR; Greenup LC; Kirkpatrick CM; Ray JE; Timmins P; Williams KM
Clin Pharmacokinet; 2011 Feb; 50(2):81-98. PubMed ID: 21241070
[TBL] [Abstract][Full Text] [Related]
34. Association of
Chen P; Cao Y; Chen S; Liu Z; Chen S; Guo Y
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289808
[TBL] [Abstract][Full Text] [Related]
35. Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1).
Strobel J; Müller F; Zolk O; Endreß B; König J; Fromm MF; Maas R
Amino Acids; 2013 Oct; 45(4):989-1002. PubMed ID: 23864433
[TBL] [Abstract][Full Text] [Related]
36. Clinical Aspects of Drug-Drug Interaction and Drug Nephrotoxicity at Renal Organic Cation Transporters 2 (OCT2) and Multidrug and Toxin Exclusion 1, and 2-K (MATE1/MATE2-K).
Saad AAA; Zhang F; Mohammed EAH; Wu X
Biol Pharm Bull; 2022; 45(4):382-393. PubMed ID: 35370262
[TBL] [Abstract][Full Text] [Related]
37. Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis.
Toyama K; Yonezawa A; Masuda S; Osawa R; Hosokawa M; Fujimoto S; Inagaki N; Inui K; Katsura T
Br J Pharmacol; 2012 Jun; 166(3):1183-91. PubMed ID: 22242910
[TBL] [Abstract][Full Text] [Related]
38. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.
Hou W; Zhang D; Lu W; Zheng T; Wan L; Li Q; Bao Y; Liu F; Jia W
Mol Diagn Ther; 2015 Feb; 19(1):25-33. PubMed ID: 25573751
[TBL] [Abstract][Full Text] [Related]
39. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.
Chen Y; Li S; Brown C; Cheatham S; Castro RA; Leabman MK; Urban TJ; Chen L; Yee SW; Choi JH; Huang Y; Brett CM; Burchard EG; Giacomini KM
Pharmacogenet Genomics; 2009 Jul; 19(7):497-504. PubMed ID: 19483665
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects.
Abebe BT; Weiss M; Modess C; Tadken T; Wegner D; Meyer MJ; Schwantes U; Neumeister C; Scheuch E; Schulz HU; Tzvetkov M; Siegmund W
J Clin Pharmacol; 2020 Mar; 60(3):312-323. PubMed ID: 31542894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
